A Phase 2 Trial of Rituximab and Corticosteroid Therapy for Newly Diagnosed Chronic Graft Versus Host Disease
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
The addition of rituximab to prednisone for the initial treatment of chronic GVHD will
increase the overall response rate, enable a more rapid and effective steroid taper.